Biodrugs

Papers
(The H4-Index of Biodrugs is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond350
Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis297
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis127
Emerging Therapy in Osteoarthritis: Mesenchymal Stem Cells, Secretomes, and Using Hydrogels to Enhance Efficacy103
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome93
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor92
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making78
Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery62
Acknowledgement to Referees61
Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials60
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart49
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies44
Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–202240
CAR-T Cells and the Kidney: Insights from the WHO Safety Database40
Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?38
Correction: Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent Endometrial Cancer: A Nationwide Cohort Study in France36
The Present and Future of Monoclonal Antibody Therapies for Multiple Sclerosis36
Cell Engineering for Increasing Production of Recombinant Proteins in Mammalian Cells36
Correction: Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review35
Progress and Challenges in the Treatment of Fabry Disease34
Malaria Vaccines: Progress to Date34
Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase33
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?32
Effectiveness of Lebrikizumab Treatment for Patients with Atopic Dermatitis Switched from Dupilumab or Tralokinumab: A 48-Week Real-World Retrospective Study32
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer31
Interleukin-23 Inhibitors in Inflammatory Bowel Disease30
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects30
Real-World Evidence on the Effectiveness and Safety of Spesolimab in the Treatment of Generalized Pustular Psoriasis Flares: A Case Series29
Acknowledgement to Referees29
0.053566932678223